Chronic Myeloid Leukemia (BCR-ABL1) · line 1 · Imatinib (CML chronic phase 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-IMATINIB-CML |
| ID | IND-CML-1L-IMATINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CML |
| Sources | SRC-ELN-CML-2020 SRC-IRIS-OBRIEN-2003 SRC-NCCN-MPN-2025 |
Notes
Standard track for CML 1L. Imatinib most accessible (НСЗУ-reimbursed generics widely available). STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-CML-1L- ALGO-CML-1L